Free Trial

Mineralys Therapeutics (MLYS) SEC Filings & 10K Form

Mineralys Therapeutics logo
$14.32 +0.06 (+0.42%)
Closing price 04:00 PM Eastern
Extended Trading
$14.31 -0.01 (-0.07%)
As of 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Mineralys Therapeutics SEC Filings

DateFilerForm TypeView
07/15/2025
4:00 PM
Mineralys Therapeutics (Issuer)
Rodman David Malcom (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/15/2025
4:01 PM
Levy Adam Scott (Reporting)
Mineralys Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/15/2025
4:02 PM
Congleton Jon (Reporting)
Mineralys Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/14/2025
3:23 PM
Mineralys Therapeutics (Subject)
Rodman David Malcom (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/11/2025
3:10 PM
Levy Adam Scott (Reporting)
Mineralys Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/11/2025
3:11 PM
Congleton Jon (Reporting)
Mineralys Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/17/2025
6:07 AM
Mineralys Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/13/2025
3:23 PM
Mineralys Therapeutics (Subject)
Rodman David Malcom (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/15/2025
6:01 PM
Mineralys Therapeutics (Issuer)
Rodman David Malcom (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2025
7:57 PM
Mineralys Therapeutics (Issuer)
Rodman David Malcom (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2025
4:31 PM
Mineralys Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/25/2025
6:01 PM
Catalys Pacific Fund, LP (Reporting)
Mineralys Therapeutics (Issuer)
Slingsby Brian Taylor (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/14/2025
3:11 PM
Mineralys Therapeutics (Subject)
Rodman David Malcom (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/09/2025
7:16 AM
Mineralys Therapeutics (Filer)
Form DEF 14A
04/09/2025
7:18 AM
Mineralys Therapeutics (Filer)
Form DEFA14A
04/09/2025
7:21 AM
Mineralys Therapeutics (Filer)
Form ARS
04/03/2025
4:36 PM
Mineralys Therapeutics (Issuer)
Rodman David Malcom (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2025
3:44 PM
Mineralys Therapeutics (Subject)
Rodman David Malcom (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/31/2025
7:15 AM
Mineralys Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/17/2025
8:04 PM
AKKARAJU SRINIVAS (Reporting)
Mineralys Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/17/2025
8:05 PM
Mineralys Therapeutics (Issuer)
Samsara BioCapital GP, LLC (Reporting)
Samsara BioCapital, L.P. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/17/2025
8:06 PM
Mineralys Therapeutics (Subject)
Samsara BioCapital, L.P. (Filed by)
Form SCHEDULE 13D/A
03/17/2025
6:56 PM
Kolchinsky Peter (Reporting)
Mineralys Therapeutics (Issuer)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund III, L.P. (Reporting)
Shah Rajeev M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/17/2025
6:58 PM
Mineralys Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SCHEDULE 13D/A
03/13/2025
4:15 PM
Mineralys Therapeutics (Issuer)
Rodman David Malcom (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2025
6:05 AM
Mineralys Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/24/2025
8:41 PM
Kolchinsky Peter (Reporting)
Mineralys Therapeutics (Issuer)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund III, L.P. (Reporting)
Shah Rajeev M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2025
5:58 PM
Mineralys Therapeutics (Issuer)
SBLENDORIO GLENN (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2025
5:58 PM
Karydas Daphne (Reporting)
Mineralys Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2025
5:58 PM
Congleton Jon (Reporting)
Mineralys Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2025
5:59 PM
Gold Alexander M (Reporting)
Mineralys Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2025
5:59 PM
DiRocco Derek (Reporting)
Mineralys Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2025
5:59 PM
Catalys Pacific Fund, LP (Reporting)
Mineralys Therapeutics (Issuer)
Slingsby Brian Taylor (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2025
5:59 PM
AKKARAJU SRINIVAS (Reporting)
Mineralys Therapeutics (Issuer)
Samsara BioCapital, L.P. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2025
5:59 PM
Mineralys Therapeutics (Issuer)
Rodman David Malcom (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2025
5:59 PM
Levy Adam Scott (Reporting)
Mineralys Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2025
5:03 AM
Mineralys Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/14/2025
5:03 AM
ADAMS STREET PARTNERS LLC (Filed by)
Mineralys Therapeutics (Subject)
Form SCHEDULE 13G/A
02/13/2025
4:29 PM
Mineralys Therapeutics (Issuer)
Rodman David Malcom (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/12/2025
6:07 AM
Mineralys Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/04/2025
7:05 AM
Mineralys Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
This tiny loophole could hand you massive winners… (Ad)

Top institutions are raising their year-end targets for one of the biggest assets out there… Several weeks ago, Standard Chartered’s Head of Digital Assets revised his target for Q2 2025 from $120k… openly acknowledging $200K is in play. And with the kind of momentum we’ve seen from this top asset - Bitcoin - in recent weeks, I wouldn’t be surprised if it hits that target in the coming months. In fact, from what I’m seeing, the stars are aligned for a bull run… and its next leg up could be just around the corner.

Just tap this link and you’ll be all set. 
01/15/2025
8:44 PM
Congleton Jon (Reporting)
Mineralys Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2025
8:45 PM
Mineralys Therapeutics (Issuer)
Rodman David Malcom (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2025
8:46 PM
Levy Adam Scott (Reporting)
Mineralys Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2025
5:21 PM
Levy Adam Scott (Reporting)
Mineralys Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/13/2025
5:34 PM
Congleton Jon (Reporting)
Mineralys Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/08/2025
7:07 AM
Mineralys Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/07/2025
4:58 PM
Catalys Pacific Fund, LP (Reporting)
Mineralys Therapeutics (Issuer)
Slingsby Brian Taylor (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/13/2024
3:37 PM
Mineralys Therapeutics (Issuer)
Rodman David Malcom (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2024
9:40 AM
Mineralys Therapeutics (Subject)
Rodman David Malcom (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/06/2024
5:43 PM
Mineralys Therapeutics (Subject)
Rodman David Malcom (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/30/2024
7:03 AM
Mineralys Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/15/2024
3:21 PM
Congleton Jon (Reporting)
Mineralys Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2024
3:22 PM
Mineralys Therapeutics (Issuer)
Rodman David Malcom (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2024
3:22 PM
Levy Adam Scott (Reporting)
Mineralys Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/11/2024
3:48 PM
Levy Adam Scott (Reporting)
Mineralys Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/11/2024
3:54 PM
Congleton Jon (Reporting)
Mineralys Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/25/2024
7:06 AM
Mineralys Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/12/2024
3:32 PM
Mineralys Therapeutics (Issuer)
Rodman David Malcom (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2024
3:20 PM
Mineralys Therapeutics (Issuer)
Rodman David Malcom (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/26/2024
8:45 PM
Catalys Pacific Fund, LP (Reporting)
Mineralys Therapeutics (Issuer)
Slingsby Brian Taylor (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:MLYS) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners